INTCO MEDICAL(SZ:300677) KAIYUAN SECURITIES·2025-04-28 06:23Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve significant growth in 2024, with revenue projected at 9.523 billion yuan (up 37.65% year-on-year) and net profit attributable to shareholders at 1.465 billion yuan (up 282.63 year-on-year) [6] - The growth is driven by industry inventory digestion, the elimination of outdated production capacity, and a 100% capacity utilization rate, alongside a recovery in glove prices [6] - The company has a strong cost and capacity advantage, with a global expansion strategy that mitigates geopolitical risks [6] - The disposable glove market is expected to grow, with global sales projected to reach 82.93 billion units and revenue of 13.6 billion USD in 2025 [7] Financial Summary - Revenue for 2024 is expected to be 9.523 billion yuan, with a year-on-year growth of 37.6% [9] - Net profit for 2024 is projected at 1.465 billion yuan, reflecting a year-on-year increase of 282.6% [9] - The gross margin for personal protective equipment is 24.24%, an increase of 10.96 percentage points [6] - The company’s earnings per share (EPS) for 2025 is estimated at 2.49 yuan, with a price-to-earnings (P/E) ratio of 9.0 [6][9] Production Capacity and Technology - The company's total production capacity for disposable gloves is expected to reach 87 billion units in 2024, a year-on-year increase of 5.33% [8] - The company operates six production bases in China, with advanced production technology and automation ensuring high efficiency and low energy consumption [8]